Clinical trials
Prostatitis clinical trials
Below are recruiting prostatitis clinical trials, each written for real people, not researchers. We’re tracking 1,368 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06096870RecruitingPhase 2
Enzalutamide with a new drug for prostate cancer that is active on PET scan
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
Bethesda, MarylandAges 18–120 - NCT07694752Recruiting
MRI study of prostate and urinary sphincter
This study uses special MRI scans to look at the muscle ring that controls urination and the base of the prostate. It may help doctors understand how these areas change with conditions like enlarged prostate or prostate cancer treatment.
Taizhou, JiangsuAges 15–90 - NCT04857502RecruitingEarly Phase 1
Tracking prostate cancer spread before lymph node surgery
This early study uses a special imaging tracer to show where prostate cancer has spread in the pelvic lymph nodes. It may help doctors better understand how well certain scans guide surgical removal of affected lymph nodes.
Los Angeles, CaliforniaAges Any age - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Birmingham, AlabamaAges 21 years+ - NCT03327675Recruiting
PET imaging test to plan personalized prostate cancer treatment
This trial tests a high-precision scan that uses a prostate cancer marker to show where cancer may be. The goal is to use the scan results to better plan treatment, especially around surgery and lymph nodes, in certain patients with prostate cancer.
LeuvenAges 18 years+ - NCT03424850RecruitingPhase 1/Phase 2
Tested different radiation doses for early prostate cancer
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
St Louis, MissouriAges 18 years+ - NCT03474913Recruiting
Upright MRI to help screen for prostate cancer
This study checks whether an MRI done while you are in an upright position can help with prostate cancer screening. If you have been advised to get a prostate MRI, the researchers may also do an ultrasound-guided biopsy to confirm results.
New York, New YorkAges 18–100 - NCT03495427RecruitingPhase 2/Phase 3
PSMA PET scan to find early prostate cancer spread
This study uses a PSMA PET scan to look for early spread of prostate cancer in men with higher-risk genetic test results (Decipher score above 0.45). It may help doctors spot metastases sooner so treatment decisions can be better targeted.
Tampa, FloridaAges 18 years+ - NCT03650595Recruiting
MRI-guided laser treatment for prostate cancer
This trial tests a minimally invasive prostate treatment using MRI guidance and a focal laser to destroy only the cancer spot (not the whole prostate). If you have low-to-intermediate risk, MRI-visible prostate cancer in a limited area, it may help control the cancer while potentially reducing treatment side effects.
Toronto, OntarioAges 40–80 - NCT03784924Recruiting
Prostate MRI study to find blood and urine cancer signals
This study enrolls men who may have prostate cancer but do not yet have a diagnosis. It uses prostate MRI along with blood and urine tests to see if specific signals can help identify prostate cancer sooner.
Ann Arbor, MichiganAges 18 years+ - NCT03802851Recruiting
Laser procedure before radiation for prostate cancer symptoms
This trial looks at whether doing a prostate “laser procedure” (called HoLEP) before starting radiation and hormone therapy can improve severe urinary symptoms and reduce urine retention problems. It is for people with prostate cancer who are planning radiation plus hormone treatment and who have significant bladder/urinary trouble.
Kansas City, KansasAges 18 years+ - NCT03833921RecruitingPhase 2
Testing abiraterone and prednisone for metastatic prostate cancer by race
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
Houston, TexasAges 18 years+ - NCT03861507Recruiting
Power ultrasound helps locate prostate treatment needles
This trial studies whether a special ultrasound method (power Doppler ultrasound) can better guide where needles go during high-dose-rate radiation treatment for prostate cancer. The goal is to improve targeting during the procedure while you receive standard treatment.
London, OntarioAges 18 years+ - NCT03893929Recruiting
Test new markers to help diagnose prostate cancer
This study looks for new biological markers in men to improve how prostate cancer is diagnosed and followed. If you have signs that might be prostate cancer, your tests may help researchers find better clues for future care.
ShatinAges 18 years+ - NCT03933670RecruitingPhase 2
MRI scan with special sugar to monitor prostate cancer on surveillance
This study uses a special MRI scan using “hyperpolarized” labeled pyruvate (a sugar-like substance) to see how prostate cancer may be behaving in people who are on active surveillance. It may help researchers monitor cancer without immediate treatment, by spotting changes earlier.
San Francisco, CaliforniaAges 18 years+ - NCT04075305Recruiting
Study measuring radiation treatment outcomes with an MR-Linac
This study follows what happens when radiation treatment is guided using an MR-Linac (a special machine that combines MRI imaging with radiation). It may help improve how radiation therapy is planned and assessed, especially for people who can safely have MRI scans.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04146077Recruiting
Active monitoring for low-risk prostate cancer
This study tests whether watching low-risk prostate cancer closely (instead of treating right away) is safe. It may help some people avoid early treatments and their side effects while still keeping a close eye on the cancer.
MoscowAges 50–75 - NCT04337580RecruitingPhase 2
Test a fatty-acid drug for docetaxel-resistant prostate cancer
This Phase 2 study tests whether blocking fatty-acid production can slow castration-refractory prostate cancer that has already progressed after docetaxel. It may help by targeting cancer growth when standard hormone-level treatments are no longer working.
Salisbury, North CarolinaAges 18 years+ - NCT04633252RecruitingPhase 1/Phase 2
Study drug plus docetaxel and abiraterone for advanced prostate cancer
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
Bethesda, MarylandAges 18–110 - NCT04692675Recruiting
MRI study to track prostate cancer in active surveillance patients
This study uses special prostate MRI scans to see how prostate cancer changes over time while you stay on active surveillance. It also looks at prostate tissue to understand your cancer’s genetics, which may help guide future decisions.
Bethesda, MarylandAges 18 years+ - NCT04732156Recruiting
Test AI and MRI scores to spot prostate cancer
This study compares how well a doctor’s MRI reading (the PI-RADS score) and a computer AI tool detect prostate cancer. It may help improve how men get targeted biopsies and avoid missing important cancers.
BordeauxAges 18–80 - NCT04763317Recruiting
Precision medicine for prostate cancer care decisions
This study tries to personalize prostate cancer care by matching treatment decisions to a person’s specific risk profile. You might be able to join if you have certain types of prostate cancer or a strong family history and meet health-function requirements.
Sutton, EnglandAges 30–70 - NCT04858880Recruiting
Personalized radiation for PSA rise after prostate surgery
This study tests a tailored (personalized) radiation plan for men whose PSA (“prostate blood test”) rises after prostate surgery but who have no detectable spread on scans. It may help control cancer growth by targeting the right area based on your situation.
JönköpingAges 18 years+ - NCT04995198Recruiting
Prostate cancer patient registry for genetics and treatment outcomes
This registry collects information from people with prostate cancer to better understand how genetics and treatments affect survival and outcomes. Your data may help researchers improve future treatment choices.
Baltimore, MarylandAges 18 years+
Hear when a new Prostatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatitis?
- Yes. Clin2 currently lists 1,368 recruiting prostatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.